Expression of the B7/BB1 Activation Antigen and its Ligand CD28 in T-Cell-Mediated Skin Diseases  by Simon, Jan C et al.
Expression of the B 7/BB 1 Activation Antigen and its 
Ligand CD28 in T-Cell-Mediated Skin Diseases 
] an C. Simon, Andrea Dietrich, Volker Mielke, * Christiane W uttig, Wolfgang Vanscheidt, Peter S. Linsley, t 
Erwin Schopf, and Wolfram Sterry* 
Departments of Dermatology. University of Freiburg. Freiburg; 'University ofUlm. Ulm. Germany; and tBristol-Myers Squibb. 
Seattle. Washington. U .S.A. 
Interactions of CD28 (on T cells) with its recently 
identified ligand B7/BBl (on antigen-presenting 
cells) have been shown to activate T cells via a major 
histocompatibility complex/ Ag-independent "alter-
native" pathway, leading to an amplification of T-
cell-mediated immune responses. The in vivo rele-
vance of these molecules for cutaneous immunity is 
presently unknown. These findings prompted us to 
study the expression ofB7/BBl and CD28 in normal 
human skin and in selected T-cell-mediated inflam-
matory skin diseases. Biopsies were obtained from le-
sional skin of patients with allergic contact dermatitis, 
lichen planus, and, as control, from basal cell carci-
noma and from healthy controls. Serial cryostat sec-
tions were stained with a panel of MoAbs directed 
against CD28, B7/BBl, CD3, CDla, and KiM8 using 
immunohistochemistry (ABC technique). CD28 ex-
pression was observed in the majority of dermal and 
R ecently, the interaction of the B7/BBl Ag (on anti-gen-presenting cells) with its ligand CD28 (on T cells) has been shown to deliver activation signals to T cells distinct from those transduced via the T-cell re-ceptor [1,2]. The B7/BBl Ag was initially identified 
by two different antibodies (BBI and B7) which were thought to 
recognize identical (or highly related) glycoproteins with a molecu-
lar weight of 44-54 kD. B7/BBl shows low constitutive expres-
sion on resting B cells, monocytes, and dendritic cells; however, 
upon stimulation. it can be readily upregulated [3 - 9]. In addition, 
B7/BB 1 is expressed on different B-ceillines, B-cell neoplasms, and 
on long-term activated T cells [3 - 5,10,11]. CD28 is a 90-kD ho-
modimeric glycoprotein expressed by T cells. thymocytes, and 
plasma cells [2 ,12]. Binding of B7 IBB 1 to CD28 leads to an aug-
mentation of several T-cell functions such as proliferation, cytokine 
production, adhesion, and cytotoxicity [13-17]. Defective signal-
ing via the B7 IBB1/CD28 pathway has been shown to cause T-cell 
tolerance [18.19]. 
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epidermal CD3+ T cells in contact dermatitis and 
lichen planus. In normal skin and basal cell carcinoma, 
CD28 was expressed only occasionally by perivascular 
T cells. In allergic contact dermatitis and lichen 
planus, B7/BBl-expression was found on dermal den-
dritic cells, on dermal macrophages, on Langerhans 
cells, focally on keratinocytes, and occasionally on 
dermal T cells. No B7/BBl immunoreactivity was de-
tected in normal skin and basal cell carcinoma. These 
findings indicate that T -cell- mediated skin diseases 
are accompanied by an influx of CD28+ T cells and 
an upregulation of B7/BBl on cutaneous antigen-
presenting cells, keratinocytes, and on some T cells. We 
speculate that "alternative" T cell-activation via the 
B7/CD28 pathway may contribute to the pathogenesis 
of these skin diseases. Key words: B7 /BB1 /CD28. ] Invest 
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Taken together, these studies indicate that interaction ofB7 IBB 1 
with CD28 delivers essential costimulatory signals to T celis, re-
sulting in effective induction and amplification ofT -cell- mediated 
immunity [1 ,2]. Whether B7/BBI/CD28-mediated signals playa 
functional role during cutaneous immune responses is presently 
unknown. To address this issue. we examined the expression of 
B7/BBl and CD28 in T-cell-mediated skin diseases. 
MATERIALS AND METHODS 
Patients Patients with allergic contact dermatitis (ACD. n = 11). lichen 
planus (LP = 8). basal cell carcinoma (BCC. n = 12) and acute urticaria 
(n = 3) were compared to normal control subjects (NS. n = 9). None of the 
patients had received prior treatment for their skin condition. Following 
mformed consent. full-thickness 4-mm punch biopsies were obtained from 
the lesional skin of the patients. In the NS group. 4-mm punch biopsies were 
taken from the volar aspects of the forearm. Samples were snap-frozen 
immediately and stored at -80 D C until use. 
Monoclonal Antibodies (MoAhs) MoAhs against the following human 
antigens were used in this study: anti-CDla (OKT6. m-immunoglobu-
lin[Ig]Gl Ortho Diagnostics. Inc .• Raritan. NJ). anti-CD3 (IOT3. mIgGl 
Biozol. Mtinchen. Germany). KiM8 (mIgGl. Dianova. Hamburg. Ger-
many). three different anti-CD28 reagents (9.3. mIgG2a. Dr. P. S. Linsley. 
Seattle. W A; Leu 28. mlgG 1. Becton Dickinson, Sunnyvale. CA; and CLB-
28/1. mIgGl. gift of Dr. Van Lier. Amsterdam. Netherlands). and three 
different anti-B7/BBI reagents (BBl. mIgM. Dr. P. S. Linsley; 104. 
mIgGl , giftofDr.J. Banchcreau, Dardilly. France; andBB1-(IgG). mIgGl, 
Becton Dickinson). 
Im.munohistoche.mistry Frozen skin specimens were embedded in Op-
timum Cutting Medium (OCT. Miles Inc .• Elkhart. IN) and 5-Jim serial 
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cryostat sections were prepared using a Crycut 2000 (Reichert & J ung, 
Nu(\bach, Germany). Air-dried, acetone-fixed frozen sections were stained 
using a four-step immunohistochemical staining protocol (ABC-technique, 
DAKO): 1) primary MoAb (mouse IgG, IgM); 2) biotin-conjugated goat-
anti-mouse IgG, or biotin-conjugated goat-anti-mouse Il-chain; 3) peroxi-
dase-conjugated streptavidin; 4) diaminobenzidine as chromogenic sub-
strate. Finally, sections were counterstained with hemalum. Double staining 
was performed as follows: 1) primary MoAb (mouse IgG, IgM); 2) biotin-
conjugated goat-anti-mouse IgG, or biotin-conjugated goat-anti-mouse 
Il-chain (no cross-reactiviry to mouse IgG); 3) peroxidase-conjugated strep-
tavidin; 4) goat-anti-horseradish peroxidase conjugated to colloidal gold (4 
nm); 5) primary MoAb (mouse IgG); 6) rabbit-anti-mouse Ig; 7) APAAP 
(alkaline-phosphatase and mouse anti-alkaline-phosphatase-IgG); 8) naph-
thol-phosphate and fast red; 9) silver enhancement (all reagents with the 
exception of the primary MoAb from DAKO). Control staining was per-
formed by replacing the primary MoAb with isotype-matched control re-
agents. Staining was evaluated by four independent observers in a blinded 
fashion using a Zeiss Axioskop equipped with a MC100 camera system. T.he 
opinions of the observers were concordant. Langerhans cell enumeration 
was performed microscopically using an optical grid, as described [20] . 
RESULTS 
CD28 was expressed by infiltrating lymphoid cells in ACD and LP 
(Fig ta, Table I) . Doublestaining using anti-CD28 and anti-CD3 
MoAb confirmed that the majority of these CD28+ cells were 
CD3+ T cells (Fig tb). CD28 was expressed by all CD4+ T cells and 
by the majority of CD8+ T cells (not shown). Staining of the same 
specimen with isotype-matched control MoAb excluded the possi-
bili ty that this CD28 staining was nonspecific (Fig te). In normal 
skin, little CD28 immunoreactivity could be detected (Fig til), 
with the rare exception of perivascular CD28+ T cells (not shown). 
In all ergic contact dermatitis (ACD) and LP, B7 JBBl was ex-
pressed by dendritic-shaped cells in the epidermis and dermis (Fig 
te) . To test whether some of these dendritic cells were Langerhans 
cells, double staining with MoAb against CDla and B7 JBBl was 
performed. These ·studies revealed that a variable portion of dermal 
and epidermal CD 1a+ Langerhans cells also expressed B7 JBB 1 (Fig 
tj,g, Table II). In epidermis, 7%-53% of Langerhans cells were 
B7 JBBl positive, whereas by contrast, the number of B7+jBB1+ 
dermal Langerhans cells was significantly higher (28% - 68%, 
Table II) . The percentage of B7+ JBB 1 + Langerhans cells showed 
considerable variation depending on the disease investigated and the 
anti-B7 JBBl MoAb used (Table II). Specifically, more Langerhans 
cells were found to be B7+ jBBl+ in LP than in ACD, and MoAb 
104 l:,\beled more Langerhans cells than MoAb BB1 (lgG) (Table 
II). In addition, B7 JBBl was expressed by dermal macrophages of 
the phagocytic subtype (KiM8+) and by dermal dendritic cells (Fig 
te, Table I). 
Often, B7 JBB1-positive cells of dendritic shape (i.e. , Langerhans 
cells, dermal macrophages, or dermal dendritic cells) were found in 
close apposition to CD28+ T cells (Fig t j). This was observed more 
frequently in the dermis than in the epidermis. Occasionally, der-
mal and epidermal T cells were found to express B7 JBB l, particu-
larly when MoAb BB1(lgG) was used (Fig te, Table I). 
In addition, focal B7 JBBl expression was observed on keratino-
cytes (Fig th). This was most pronounced in areas overlying dense 
dermal lymphocytic infiltrates (Fig th) and was detected best when 
MoAb 104 or BBl (lgM) were used (Table I). Double staining 
demonstrated close contact of CD28+ T cells and B7+ JBB 1 + kerati-
nocytes (Fig ti) . Again, staining with isotype-matched control 
MoAb excluded the possibility that B7 JBBl staining was nonspe-
cific (Fig te). Finally, no B7 JBBl expression could be detected in 
normal skin (Fig tk) or in non - T -cell- mediated skin diseases 
such as BCC (Fig 11). 
DISCUSSION 
This study examined the expression of B7 JBBl and its ligand 
CD28 in two important T-cell-mediated inflammatory skin dis-
eases, ACD and LP. W e have shown CD28 to be expressed by the 
majority ofT cells that infiltrate the skin in ACD and LP, whereas 
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in normal skin, CD28 was found only occasionally on perivascular 
T cells. 
Thus far, only few srudies have examined the in vivo distribution 
of CD28, showing it to be restricted to lymphoid cells in lymph 
node, spleen, tonsil and thymus [21,22]. More information on the 
cellular distribution of CD28 has been gained from in vitro studies. 
For example, CD28 is expressed by the majority of CD4+ and on 
50% of CD8+ T cells (particularly CTL) isolated from human pe-
ripheral blood [2,12] . In our srudy, all CD4+ T cells infiltrating the 
skin expressed CD28, and approximately 70% of CD8+ cells were 
CD28 positive. 
We observed B7 JBB 1 to be expressed by Langerhans cells in LP 
and ACD but not in normal skin. Importantly, B7 JBBI was not 
expressed by all Langerhans cells: 1) the percentage of 
B7 JBB 1-positive Langerhans cells was higher in derrnis than in 
epidermis; 2) more Langerhans cells were B7 JBB I + in LP than in 
ACD; and 3) the percentage ofB7 JBB1-positive Langerhans cells 
differed depending on the anti-B7 JBBl MoAb used, raising the 
possibility that these reagents detect disparate forms of B7 JBBI 
([23 -25], detailed discussion below). 
Taken together, these data suggest that Langerhans cells only 
express B7 JBBI upon in vivo activation by antigen such as contact 
sensitizers. Following such activation, Langerhans cells are thought 
to migrate from epidermis into dermis, where they enter afferent 
lymphatics to travel into the draining lymph nodes [26,27]. During 
this process Langerhans cells undergo distinct phenotypic and func-
tional changes that have been termed " maruration" [26,27]. Specif-
ically, Langerhans cells upregulate their surface expression of major 
histocompatability complex Ag, and of accessory molecules, and, as 
a result, increase their capacity to stimulate resting T cells [26,27]. 
Similar changes have been observed during short-term tissue culture 
of Langerhans cells [26,27]. Our hypothesis that only activated 
Langerhans cells express B7 JBBl is supported by recent in vitro 
studies demonstrating B7 JBBl to be expressed exclusively by cul-
tured Langerhans cells but not by freshly isolated Langerhans cells 
[9,28]' Upregulation ofB7 JBBl may be responsible for the "func-
tional maturation" of Langerhans cells as they leave the epidermis . 
This notion is supported by our finding that close apposition of 
B7 JBB1-positive Langerhans cells and CD28-positive T cells was 
more frequent in dermis than in epidermis. 
Furthermore, we found B7 JBBl on dermal macrophages and 
dendritic cells and on some T cells in LP and ACD, but not in 
normal skin. This observation is consistent with in vitro data, report-
ing B7 JBBl to be expressed by activated dendritic cells, macro-
phages, and T cells [5 ,7,8,10,11,16]. 
In ACD and in LP we also detected focal B7 JBBl staining on 
keratinocytes, particularly in areas overlying dense lymphocytic in-
filtrates. The cellular distribution of B7 JBB 1 on keratinocytes re-
sembled the "chicken-wire pattern" reported for intercellular adhe-
sion molecule-l (ICAM-l) [29,30]. Similar B7 JBBl staining on 
keratinocytes was recently detected in lesional psoriatic [31] and 
eczematous:j: skin. III vitro studies from our laboratory [32], as well as 
from others [31,33] indicate that activated keratinocytes express a 
"B7-like molecule" that differs from B7 JBBl expressed by acti-
vated B cells. Recently, CD28 ligands different from B7 JBB 1 have 
been identified and named B70, B7-2, and B7-3 [23-25]. Whether 
the "B7-like molecule" on KC represents B70, B7-2, or B7-3 is 
currently unknown. We do know however, that the "B7-like mol-
ecules" on keratinocytes, as well as B7-l transfected into keratino-
cytes, serve a functional role in the binding and activation of CD28+ 
T cells [32,34,35]. 
Finally, in our srudy, B7 JBBl expression was detected exclu-
sively in T -cell - mediated skin diseases, but not in non - T -cell-
mediated conditions or in normal skin. These findings suggest that 
B7 JBB 1 might be induced by factors released from infiltrating 
* Ferbel B, Gaspari AA: Expression of the antigen presenting cell mole-
cule B7 in normal human skin (abstr) . Proc 8t1, Itll COllgress of I",,,,,II/o[ogy, 
Springer, Budapest 671, 1992. 
Figure 1. Expression ofB7 jBBl and CD28 in T-cell-mediated inflammatory skin diseases. a) Lichen planus: CD28 is expressed by infiltrating T 
cells (MoAb Leu28; bar, 400 /Lm) ; b) allergic contact dermatitis: C03 (red), CD28 (black), the majority of dermal T cells are CD3+jCD28+ (MoAbs 
IOT3jLeu28; bar, 63/Im); c) lichen planus: same specimen as shown in (a) and (h) stained with an irrelevant IgG 1 excluding unspecific staining (X63Ag8; bar, 
400 /Lm); d) normal skin: no CD28 immunoreactivity (MoAb Leu28; bar, 100/Lm); e) allergic contact dermatitis: B7/BB! on epidermal Langerhans cells 
(arrowheads) and in dermis on dendritic cells, macrophages, and some T cells (arrows) (MoAb BBl-lgG; bar, 400Illn);}) allergic contact dermatitis: COla (red), 
B7 JBBI (black) , a dermal LC is COla+ jB7/BBl+ (arrowhead), (-), dermoepidermaljunction (MoAbs OKT6jl04; bar, 63/Lm);g) lichen planus: COla (red), 
B7 JBD 1 (black), epidermal (arrowheads) , and dermal LC (arrows) are COla+ ID7 JDDI +, (-), dermoepidermal junction (MoAbs OKT6jl04; bar, 100/Lm); h) 
lichen planus: D7/DD 1 expression by keratinocytes (arrowh eads) , (-) dermoepidermaljunction (MoAb 104; bar, 63/1m); i) allergic contact dermatitis, bullous 
patch test reaction: CD28 (red), B7 JDD 1 (black), close contact of C028+T cells and B7/BBI + keratinocytes (arrowheads), (MoAbs Leu28/104; bar, 63/1m);)} 
allergic contact dermatitis: C028 (black), D7 JDD 1 (red), close contact of C028+ T cells and D7/DD 1 + dermal dendritic ce lls (arrowheads), (-) dermoepidermal 
junction (MoAb Leu 28jDDI-IgG; bar, 63/1m); k) normal skin: no D7 JDDI immunoreactivity (MoAb 104; bar, 100 /1m); i) basal cell carcinoma: no D7 JDDI 
immunoreactivity in epidermis, dermis, or tumor (arrowh ead) (MoAb 104; bar, 100/lm). 
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Table I. Summary of the Immunohistochemical Results' 
Disease 
Ag MoAb 
LP (n = 8) 
B7/BBt t04 
BB1(IgM) 
BBt(IgG) 
CD28 Leu 28 
9.3 
CLB-28/t 
ACD (n = 11) 
B7/BBt t04 
BB1(IgM) 
BB1(IgG) 
CD28 Leu 28 
9.3 
CLB-28/1 
BCC (n = t2) 
B7/BB1 104 
BB1(IgM) 
BB1(IgG) 
CD28 Leu 28 
9.3 
CLB-28/1 
NS (n = 9) 
B7/BB1 104 
BB1(IgM) 
BB1(IgG) 
CD28 Leu 28 
9.3 
CLB-28/1 
Langerhans Cells 
++ 
+ 
+ 
++ 
+ 
+ 
Epidermis 
Keratinocytes T Cells 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Langerhans Cells 
++ 
+ 
+ 
++ 
+ 
+ 
Dermis 
Dendritic Cells/Ma 
++ 
+ 
+ 
++ 
+ 
+ 
T Cells 
• Staining was evaluated in a semiquantitative fashion as described [20]: ++, strong specific staining; +, specific staining; (+), weak specific staining; -, no immunoreactivity. 
• A minority of cells stain positively with the MoAb. 
CD28+ T cells . This hypothesis is supported by 1) our own finding 
of close physical contact of CD28+ T cells and B7+ JBB I + cells, and 
2) the ill vitro observation that T-cell products such as interleukin 
(IL)2, IL4, and interferon (IFN)y upregulate B7 JBBI on antigen 
presenting cells [7,10]. Using anti-B7 MoAb different from ours, 
other investigators observed faint B7 JBBI immunoreactivity on 
Langerhans cells or keratinocytes in normal skin [33,34], raising the 
possibility that their reagents detect other CD28-ligands such as 
B7-2, B7-3. or B70 [23-25]. 
We conclude that B7 JBB 1 is expressed by professional cutaneous 
antigen-presenting cells, focally by keratinocytes, and by some T 
cells in lesional skin of patients with allergic contact dermatitis and 
lichen planus. Its ligand CD28 is found on the majority ofT cells 
infiltrating these lesions. No significant amounts of B7 JBBI or 
CD28 were detected in non- T-cell-mediated skin diseases or in 
normal skin. Based on these findings , we speculate that B7 JBBI is 
induced during T -cell - mediated cutaneous immune responses, and 
Table II. B7/BBI-Expression by Langerhans Cells' 
% ofB7/BB1+/CD1a+ 
Disease Langerhans Cells (± SD) 
MoAb 
LP 
104 
BBt(IgG) 
ACD 
104 
BB1(IgG) 
Epidermis 
53 ± 14.7 
7 ± 2.6 
24 ± 8.7 
to ± 0.7 
Dermis 
68± 4 
41 ± 11.5 
55 ± 19 
28 ± 14 
• Langherhans Cel l enumerations were performed as described [20]. Pooled data 
from patients with LP (n = 5) and ACD (n = 7) arc expressed as mean % ofCDla+/ 
B7+ cells ± SO. 
contributes within skin to the adhesion, activation, and cytotoxic 
activity of CD28+ T cells. 
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